Home Cart Sign in  
Chemical Structure| 845614-11-1 Chemical Structure| 845614-11-1

Structure of Bitopertin
CAS No.: 845614-11-1

Chemical Structure| 845614-11-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Bitopertin is a noncompetitive inhibitor of glycine reuptake with IC50 of 25 nM.

Synonyms: RG1678; RO4917838; R-1678

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Bitopertin

CAS No. :845614-11-1
Formula : C21H20F7N3O4S
M.W : 543.46
SMILES Code : O=C(N1CCN(C2=NC=C(C(F)(F)F)C=C2F)CC1)C3=CC(S(=O)(C)=O)=CC=C3O[C@@H](C)C(F)(F)F
Synonyms :
RG1678; RO4917838; R-1678
MDL No. :MFCD18251496
InChI Key :YUUGYIUSCYNSQR-LBPRGKRZSA-N
Pubchem ID :24946690

Safety of Bitopertin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H320-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • GlyT1

    GlyT1, IC50:22 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01192906 Schizophrenia Phase 3 Completed - -
NCT01234779 Schizophrenia Phase 2 Completed - -
NCT01235559 Schizophrenia Phase 3 Completed - -
NCT01235585 Schizophrenia Phase 3 Completed - -
NCT01636492 Healthy Volunteer Phase 1 Completed - New Zealand ... More >> Christchurch, New Zealand, 8011 Less <<
NCT01192880 Schizophrenia Phase 3 Completed - -
NCT03271541 Beta-Thalassemia PHASE2 COMPLETED 2018-06-29 Centro della Microcitemia e de... More >>lle Anemie Congenite - Ospedale Galliera; Oncologia /Cardiologia, Genova, Liguria, 16128, Italy|Ospedale Maggiore di Milano; Cardio-Metabolic Diseases, Milano, Lombardia, 20122, Italy|Chronic Care Center, Baabda, 1003, Lebanon|Siriraj Hospital; Division of Haematology-Oncology, Bangkok Noi, 10700, Thailand Less <<
NCT01674361 Obsessive-Compulsive Disorder Phase 2 Completed - -
NCT02019290 Healthy Volunteer Phase 1 Withdrawn March 31, 2014 -
NCT05828108 Steroid-refractory Diamond-Bla... More >>ckfan Anemia (DBA) Less << PHASE1|PHASE2 RECRUITING 2029-11-01 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT01356550 Healthy Volunteer PHASE1 COMPLETED 2025-10-11 Rennes, 35042, France|Moscow, ... More >>117192, Russian Federation|Moscow, 117292, Russian Federation Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.84mL

0.37mL

0.18mL

9.20mL

1.84mL

0.92mL

18.40mL

3.68mL

1.84mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories